Wuhan Wansheng Biotechnology Safety Rating & Test Results
As of 9 Aug 2026, Finnrick has published 248 independent lab tests of 12 peptides from Wuhan Wansheng Biotechnology: 173 passed and 75 failed under the default public standard, Purity Focus (HPLC purity at least 99.5%, fill within ±35% of the label claim). The latest test is dated 22 Jul 2026.
Finnrick ratings are recency-weighted pass percentages: newer tests count more, and vendors with thin test histories are pulled toward the peer baseline for that peptide, so a single result cannot look too certain. Samples are analyzed by independent partner laboratories and the results are published by Finnrick Analytics, which does not sell peptides and does not accept payment to alter ratings. Corrections to published data are recorded at finnrick.com/corrections.
Purchased from Wuhan Wansheng Biotechnology? Submit a sample to Finnrick for free independent lab testing — results are published publicly.
Are you Wuhan Wansheng Biotechnology? Finnrick offers professional testing services and a public launch program for peptide vendors.
Interactive charts, prices, and test history for this page load with JavaScript; the facts above are from Finnrick's published test database.
| Peptide | Finnrick rating | Lab tests | Latest test |
|---|---|---|---|
| BPC-157 | 44% | 19 | 23 Jun 2026 |
| Cagrilintide | 58% | 14 | 6 May 2026 |
| CJC-1295 | 28% | 7 | 6 Mar 2026 |
| GHK-Cu | 90% | 22 | 12 Jun 2026 |
| Ipamorelin | 69% | 14 | 17 Jul 2026 |
| Melanotan II | 64% | 6 | 1 Jul 2026 |
| PT-141 | 58% | 4 | 19 Jan 2026 |
| Retatrutide | 86% | 70 | 22 Jul 2026 |
| Semaglutide | 66% | 5 | 22 Jun 2026 |
| TB-500 | 41% | 9 | 23 Jun 2026 |
| Tesamorelin | 28% | 26 | 24 Jun 2026 |
| Tirzepatide | 88% | 52 | 1 Jul 2026 |